HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new follow-up study clinical trial data from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Mid-Atlantic Section of the American Urological Association Meeting in Hamilton, Bermuda next week on October 20. The paper is authored by leading clinical research investigators participating in the U.S. clinical trials of NX-1207.
